No-reflow'a güncel yaklaşım

KIRMA, Cevat; gunes, yilmaz; Boztosun, Bilal

No-reflow'a güncel yaklaşım

Bilal BOZTOSUN, (Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kardiyoloji Kliniği, İstanbul, Türkiye)

Yılmaz GÜNEŞ, (Özel Avrupa Şafak Hastanesi, Kardiyoloji Bölümü, İstanbul, Türkiye)

Cevat KIRMA (Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Kardiyoloji Kliniği, İstanbul, Türkiye)

Anadolu Kardiyoloji Dergisi

9 2

Yıl: 2006 Cilt: 6 Sayı: 3 Sayfa Aralığı: 255 - 260 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

No-reflow'a güncel yaklaşım

Öz:

Epikardiyal kan akımının sürdürülmesi her zaman mikrovasküler dolaşımı ve doku perfüzyonunu sağlamamaktadır. “No-reflow” adı verilen olaydan sorumlu mekanizmalar iyi bilinmemektedir. Ayrıca etki eden mekanizma hastalar arasında farklılık gösterebilmektedir. Doku perfüzyonun sağlanmasının sol ventrikül fonksiyonlarını olumlu yönde etkilediği bilinmektedir. Etkin tedavinin sağlanması için sorumlu mekanizmaların daha iyi bilinmesi gerekmektedir.

Anahtar Kelime: Tanı Anjiyoplasti, transluminal, perkutan koroner Mikrosirkülasyon Seyir Görülme sıklığı Miyokardiyal reperfüzyon hasarı Koroner darlık Koroner dolaşım

Konular: Kalp ve Kalp Damar Sistemi

Current management of no-reflow

Öz:

Restoration of epicardial blood flow is not necessarily associated with microvascular and tissue perfusion. The mechanisms responsible for no-reflow are uncertain and prevailing mechanism operating in the individual patient may also differ. Restoration of perfusion at the tissue level is expected to have beneficial effects on left ventricular function. Therapeutic approach to such a phenomenon requires knowledge of mechanisms, methods of diagnosis and response to treatment modalities.

Anahtar Kelime: Incidence Myocardial Reperfusion Injury Coronary Stenosis Coronary Circulation Diagnosis Angioplasty, Transluminal, Percutaneous Coronary Microcirculation Prognosis

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in dogs. J Clin Invest 1974; 54: 1496-508.
2. Safian RD. No-reflow. In: Safian RD, Freed M., editors. The Manual of Interventional Cardiology. 3rd ed. Royal Oak, Mich. : Physicians' Press; 2001. p.413-9.
3. Kondo M, Nakano A, Saito D, Shimono Y. Assessment of “microvascular no-reflow phenomenon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction. J Am Coll Cardiol 1998; 32: 898-903.
4. Galiuto L, Lombardo A, Maseri A, Santoro L, Porto I, Cianflone D, et al. Temporal evolution and functional outcome of no-reflow: sustained and spontaneously reversible patterns following successful coronary recanalization. Heart 2003; 89: 731-7.
5. L Galiuto. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenic classification. Heart 2004; 90: 123-5.
6. Reffelmann, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart 2002; 87: 162-8.
7. Popma JJ,Topol EJ, Hinohara T,Pinkerton CA, Baim DS,King 3rd SB, et al. Abrupt vessel closure after directional coronary atherectomy. The U.S. Directional Atherectomy Investigator Group. J Am Coll Cardiol 1992; 19: 1372 - 9.
8. Kunichika H, Ben-Yehuda O, Lafitte S, Kunichika N, Peters B,DeMaria AN. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. J Am Coll Cardiol 2004; 43: 276-83.
9. Richard V, Kaeffer N, Tron C, Thuillez C.. Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion. Circulation 1994; 89: 1254-61.
10. Gailuto L, DeMaria AN, del Balzo U, May-Newman K,Flaim SF,Wolf PL et al. Ischemia-reperfusion injury at the microvascular level: treatment by endothelin-a selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102: 3111-6.
11. de Lemos JA, Antman EM, Giugliano RP, McCabe CH, Murphy SA, Van de Werf F et al. ST-segment resolution and infarct related artery patency and flow after thrombolytic therapy. Am J Cardiol 2000; 85: 299-304.
12. Piana RN, Paik GY, Moscucci M, Cohen DJ, Gibson CM, Kugelmass AD, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994; 89: 2514-8.
13. Vallejo E, Pena-Duque MA, Norono O, Ban Hayashi E, Gaspar J, Villavicencio R et al. The no-reflow phenomenon: its incidence and clinical characteristics in a series of cases. Arch Inst Cardiol Mex 1998; 68: 247-52.
14. Resnic FS, Wainstein M, Lee MKY, Behrendt D, Wainstein RV, Ohno-Machado L, et al. no reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003; 145: 42-6.
15. Safian RD, Niazi KA, Strzelecki M, Lichtenberg A,May MA, Juran N, et al. Detailed angiographic analysis of high-speed mechanical rotational atherectomy in human coronary arteries. Circulation 1993; 88: 961-8.
16. Warth DC, Leon MB, O'Neill WW, Zacca N, Polissar NL, Buchbinder M, et al. Rotational atherectomy multicenter registry: Acute results, complications and 6-month angiographic follow-up in 709 patients. J Am Coll Cardiol 1994; 24: 641-8.
17. Abbo KM, Dooris M, Glazier S, O'Neill WW, Byrd D, Grines CL, et al. No-reflow after percutaneous coronary intervention: Clinical and angiographic characteristics, treatment and outcome. Am J Cardiol 1995; 75: 778-82.
18. Morishima I, Sone T, Okamura, A,Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202-9.
19. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, et al. Clinical implications of the “no reflow” phenomenon. Circulation 1996; 93: 223-8.
20. van't Hof A, Liem A, de Boer M, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Lancet 1997; 350: 615-9.
21. Abacı A. Miyokard perfüzyonunun anjiyografik olarak değerlendirilmesi. Türk Kardiyoloji Seminerleri 2002; 2: 257-63.
22. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-30.
23. L Galiuto. Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenic classification. Heart 2004; 90: 123-5.
24. Kloner RA, Dai W. Definition and biology of no-reflow. J Am Coll Cardiol 2004; 43: 284-6.
25. Ito H, Okamura A, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93: 1993-9.
26. Ragosta M, Camarano G, Kaul S, Powers ER, Sarembock IJ, Gimple LW. Microvascular integrity indicates myocellular viability in patients with recent myocardial infraction: new insights using myocardial contrast echocardiography. Circulation 1994; 89: 2562-9.
27. Sakuma T, Hayashi Y, Sumi K, Imazu M, Yamakido M. Prediction of short- and intermediate-term prognoses of patients with acute myocardial infraction using myocardial contrast echocardiography one day after recanalization. J Am Coll Cardiol 1998; 32: 890-7.
28. Wu KC, Zerhouni EA, Judd RM, Lugo-Olivieri CH, Barouch LA, Schulman SP, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 998; 97: 765-72.
29. Reffelmann T, Kloner RA. Is microvascular protection by cariporide and ischemic preconditioning causally linked to myocardial salvage? Am J Physiol Heart Circ Physiol 2003; 284: H1134-41.
30. Hale SL, Dae MW, Kloner RA. Hypothermia during reperfusion limits “no-reflow” injury in a rabbit model of acute myocardial infarction. Cardiovasc Res 2003; 59: 715-22.
31. Zhao X-Q, Theroux P, Snappinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction: angiographic results from the PRISM-PLUS trial (platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms) . Circulation 1999; 100: 1609-15.
32. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observation from the TIMI 14 trial. Circulation 2000; 101: 239-43.
33. Gibson CM, Cohen DJ, Cohen EA, Lui HK, Murphy SA, Marble SJ, et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Am J Cardiol 2001; 87: 1293-5.
34. Grantham JA, Hasdai D, Holmes DR. Antiplatelet therapy with abciximab in percutaneous intervention of thrombus containing bypass grafts. Circulation 1998: 98 (suppl I): I-572.
35. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol 1997; 80: 985-8.
36. Quintana M, Kahan T, Hjemdahl P. Pharmacological prevention of reperfusion injury in acute myocardial infarction. A potential role for adenosine as a therapeutic agent. Am J Cardiovasc Drugs 2004; 4: 159-67.
37. Rezkalla SH; Kloner RA. No-reflow phenomenon. Circulation. 2002; 105: 656-62.
38. Pislaru SV, Barrios L, Stassen T, Jun L, Pislaru C, Van de Werf F. Infarct size, myocardial hemorrhage, and recovery of function after mechanical versus pharmacological reperfusion. Effects of lytic state and occlusion time. Circulation. 1997; 96: 659-66.
39. Tanjiyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-9.
40. Ito H, Tanjiyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior myocardial infarction. J Am Coll Cardiol 1999; 33: 654-60.
41. Stone GW, Brodie BR, Griffin JJ, Morice MC, Costantini C, Overlie PA, et al, on behalf of the Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Improved short-term outcomes of primary coronary stenting compared to primary balloon angioplasty in acute myocardial infarction at experienced centers: the PAMI study group experience. J Intervent Cardiol 1999; 12: 101-8.
42. Antoniucci D, Valenti R, Migliorini A, Moschi G, Bolognese L, Cerisano G, et al. Direct.artery stenting without predilatation and no-reflow in patients with acute myocardial infarction. Am Heart J 2001; 142: 684-90.
43. Limburno U, Michelli A, De Carlo M, Amoroso G, Rossini R, Palagi C, et al. Mechanical prevention of distal embolization during primary angioplasty. Safety, feasibility, and impact on myocardial perfusion. Circulation 2003; 108: 171-6.
44. Yip HK, Chen MC, Chang HW, Kuo FY, Yang CH, Chen SM, et al. Transradial application of PercuSurge GuardWire device during primary percutaneous intervention of infarct-related artery with high-burden thrombus formation. Catheter Cardiovasc Interv 2004; 61: 503-11.
45. Karadağ B; Eberli FR, Roffi M. Distal emboli protection intervention in native coronary artery occlusion. Anadolu Kardiyol Derg 2003: 3; 279-82.
46. Kloner RA, Alker K, Campbell C, Figures G, Eisenhauer A, Hale S. Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi? Circulation 1989; 79: 1125-36.
47. Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the “no-reflow” phenomenon during coronary reperfusion. Circulation 1984; 70: 513-21.
48. Ellis SG, Popma JJ, Buchbinder M, Franco I, Leon MB, Kent KM, et al. Relation of clinical presentation, stenosis morphology, and operator technique to the procedural results of rotational atherectomy and rotational atherectomy-facilitated angioplasty. Circulation 1994; 89: 882- 92.
49. Demir İ, Yılmaz H, Belgi A, Sancaktar O. Treatment of no-reflow phenomenon with intracoronary verapamil after primary stent deployment during myocardial infarction. Anadolu Kardiyol Derg 2001: 3; 213-6.

APA	Boztosun B, gunes y, KIRMA C (2006). No-reflow'a güncel yaklaşım. , 255 - 260.
Chicago	Boztosun Bilal,gunes yilmaz,KIRMA Cevat No-reflow'a güncel yaklaşım. (2006): 255 - 260.
MLA	Boztosun Bilal,gunes yilmaz,KIRMA Cevat No-reflow'a güncel yaklaşım. , 2006, ss.255 - 260.
AMA	Boztosun B,gunes y,KIRMA C No-reflow'a güncel yaklaşım. . 2006; 255 - 260.
Vancouver	Boztosun B,gunes y,KIRMA C No-reflow'a güncel yaklaşım. . 2006; 255 - 260.
IEEE	Boztosun B,gunes y,KIRMA C "No-reflow'a güncel yaklaşım." , ss.255 - 260, 2006.
ISNAD	Boztosun, Bilal vd. "No-reflow'a güncel yaklaşım". (2006), 255-260.

APA	Boztosun B, gunes y, KIRMA C (2006). No-reflow'a güncel yaklaşım. Anadolu Kardiyoloji Dergisi, 6(3), 255 - 260.
Chicago	Boztosun Bilal,gunes yilmaz,KIRMA Cevat No-reflow'a güncel yaklaşım. Anadolu Kardiyoloji Dergisi 6, no.3 (2006): 255 - 260.
MLA	Boztosun Bilal,gunes yilmaz,KIRMA Cevat No-reflow'a güncel yaklaşım. Anadolu Kardiyoloji Dergisi, vol.6, no.3, 2006, ss.255 - 260.
AMA	Boztosun B,gunes y,KIRMA C No-reflow'a güncel yaklaşım. Anadolu Kardiyoloji Dergisi. 2006; 6(3): 255 - 260.
Vancouver	Boztosun B,gunes y,KIRMA C No-reflow'a güncel yaklaşım. Anadolu Kardiyoloji Dergisi. 2006; 6(3): 255 - 260.
IEEE	Boztosun B,gunes y,KIRMA C "No-reflow'a güncel yaklaşım." Anadolu Kardiyoloji Dergisi, 6, ss.255 - 260, 2006.
ISNAD	Boztosun, Bilal vd. "No-reflow'a güncel yaklaşım". Anadolu Kardiyoloji Dergisi 6/3 (2006), 255-260.